ESSAY
=====

As an undergraduate student at Dartmouth College in the mid-1950s, I always looked forward to the yearly visit of the poet Robert Frost, a former student, who would read his poetry to an enthralled audience. One of my favorites was "The Road Not Taken", which ends with the line: "Two roads diverged in a wood, and I---I took the one less traveled by, and that has made all the difference."
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When I entered the field of glycobiology, there were only a handful of investigators working in this area. My first experience in this field was in the lab of Luis Glaser at Washington University where we showed that baker\'s yeast contains a phosphomannomutase that converts mannose 6-phosphate (Man-6-P) to Man-1-P for the formation of GDP-mannose, a donor for mannan synthesis. I worked on this project during the summer before I entered medical school, and while I found the experience thrilling, the topic seemed to have little relevance to medicine. I never imagined that 37 years later mutations in this enzyme would turn out to be the most common cause of a newly recognized group of genetic disorders termed congenital disorders of glycosylation. It is a personal example of a well-established truth in science, that studies of simpler organisms often lead to major advances in clinical medicine.

During my time with Luis, I learned that most mammalian cells also contain a coat of sugar on their surfaces, termed the "glycocalyx." There was little known about the structure or function of the molecules that comprise the glycocalyx, but it had been shown that one of the component sugars, sialic acid, served as a receptor for viral attachment. I also became aware of the work of Walter Morgan, Winifred Watkins, and Elvin Kabat showing that the ABO blood group determinants were carbohydrate in nature, with the A and B determinants differing by a single sugar that was selectively recognized by antibodies and plant lectins. This raised the possibility that the sugars in the glycocalyx might also be arranged in specific sequences to serve as information molecules in cell--cell interactions. Energized by this possibility, I decided to take the road less traveled and enter the emerging field of glycobiology.

After working several summers in the Glaser lab, I went to Victor Ginsburg\'s lab at the NIH for two years to gain more experience in this area. It was an exciting time to be at the NIH, but one event was particularly important for my career. This was the start of my long-term scientific collaboration with my wife Rosalind, who had just received her Ph.D. in biochemistry, studying glycogen biosynthesis. As Joe Goldstein has eloquently pointed out, if you are fortunate to hook up with the right collaborator, the combined efforts of two minds can be a powerful force toward discovery. But he warned that one must be careful to choose a partner who is smarter than you ([@B1]). Certainly in my case I had the perfect partner.

After two years at the NIH we were anxious to start our own lab and were fortunate to obtain faculty positions in the Department of Medicine at Washington University. One of the attractive features of the department was its strong support for the performance of basic research by its faculty. There was a recognition that basic research ultimately propels advances in clinical medicine. With the belief that knowledge of the structure of protein-linked oligosaccharides was fundamental for understanding the diversity and function of these molecules and for gaining insight into the enzymes involved in their synthesis, we set out to determine the structures of the N- and O-linked glycans of the monoclonal antibodies of patients with multiple myeloma as this provided large amounts of homogeneous glycoproteins synthesized by a single clone of plasma cells. As this work progressed and N-linked structures of other proteins became available, we noted a striking similarity of the core regions of high-mannose and complex-type glycans with each other and with the yeast mannan structures determined by Clint Ballou. A few years later the significance of this observation became clear when our lab, as well as the labs of Phil Robbins and Don Summers, showed that both high-mannose and complex-type glycans are derived from a common oligosaccharide of 14 sugars (three glucoses, nine mannoses, and two *N*-acetyl glucosamines) that is transferred from a lipid-carrier to the nascent protein in the endoplasmic reticulum (ER) and then is processed in the ER and the Golgi to produce these two types of structures. It appears that as multicellular organisms developed and required a greater array of glycans, Mother Nature chose to use the existing system of high-mannose oligosaccharide synthesis as the template for generating the required oligosaccharide diversity rather than developing an entirely new biosynthetic pathway. Interestingly, one of the glucose residues of the oligosaccharide was subsequently found to serve a special function in facilitating the folding of recipient glycoproteins mediated by lectin-containing chaperones, as shown by Ari Heleneus, Armando Parodi, and John Bergeron. This is a wonderful example of carbohydrate--lectin interactions serving an essential biological role.

Our initial effort to study the biological role of cell surface glycans involved the use of toxic lectins such as ricin to select Chinese hamster ovary (CHO) cells that fail to bind the lectins due to blocks in the synthesis of protein and lipid-linked oligosaccharides. This approach, taken simultaneously by Pam Stanley, was successful in selecting cells with a variety of defects in glycan biosynthesis. The study of these mutant cells provided a number of new insights into the biosynthetic pathways for glycan assembly, but the alterations in cell behavior were modest, a disappointing outcome. It turned out that CHO cells grown in tissue culture were not good models for studying the biological roles of glycans, for when the same genes were inactivated in mice, the phenotypes were often quite dramatic, in some cases resulting in embryonic lethality. This demonstrated that the proper synthesis of glycans is important for normal development and tissue function. The growing number of genetic defects that give rise to the congenital disorders of glycosylation leaves no doubt as to the essential nature of protein and lipid glycosylation. As frequently happens in research, there have been numerous and often unexpected uses of the lectin-resistant cell lines. The most spectacular example comes from the work of Jim Rothman, with whom I am sharing this year\'s E. B. Wilson Award along with Randy Schekman. Jim used our 15B ricin-resistant cell line as a key reagent in his brilliant studies of COPI-mediated vesicular transport in the Golgi.

While we were in the midst of our studies of the N-linked oligosaccharide processing pathway, Bill Sly reported his discovery that Man-6-P residues in the high-mannose units of lysosomal acid hydrolases serve as recognition markers for the targeting of this family of proteins to lysosomes. This immediately raised the question of how these residues are synthesized. It was initially assumed that there must be an ATP-dependent kinase that carried out this reaction, but attempts to detect such an activity were unsuccessful. In view of this, Ira Tabas, an M.D.-Ph.D. student in the lab who had performed the \[^3^H\]mannose pulse-chase experiments demonstrating oligosaccharide processing on the vesicular stomatitis virus G glycoprotein, and I decided it might be informative to carry out a similar experiment with β-glucuronidase, a lysosomal acid hydrolase. This would tell us the timing of the phosphorylation event, which would provide clues as to where the phosphorylation occurred, e.g., ER versus Golgi. As it turned out, the experiment was very successful and set us on the path toward discovering a novel biosynthetic pathway, but not before we had to sort out some puzzling results. Ira readily detected phosphorylation of mannose residues on the newly synthesized β-glucuronidase, but these were resistant to alkaline phosphatase, whereas Sly had shown that this treatment removes the phosphate from the β-glucuronidase that he had isolated from tissues. My first reaction was that Ira had messed up the assay, but the finding was reproducible, so we were convinced by the data and tried to figure out what it was telling us. Eventually we realized that the phosphorylated mannose might be in the form of a diester, which would be resistant to phosphatase treatment. This indeed turned out to be the case, and after considerable effort we were able to show that the diester linkage involved a covering *N*-acetylglucosamine residue. This immediately suggested a biosynthetic scheme involving two enzymes whereby GlcNAc-1-P is first transferred from the nucleotide sugar UDP-GlcNAc to a mannose residue to form a GlcNAc-P-Man diester, and then the GlcNAc is excised to form the Man-6-P monoester described by Sly ([@B3]). At this point, Marc Reitman and Ajit Varki joined the project, and within a very short time we were able to demonstrate the presence of the two postulated enzymes. Proof that we had identified the correct pathway came from our studies showing that fibroblasts of patients with I-cell disease, an autosomal recessive lysosomal storage disorder characterized by hypersecretion of acid hydrolases due to the failure to synthesize the Man-6-P recognition marker, lack GlcNAc-P transferase activity ([@B2]). Similar findings were reported simultaneously by the group of Kurt von Figura in Germany.

These initial studies set us on a path that we followed for the next 30 years, addressing key questions such as how GlcNAc-P transferase recognizes acid hydrolases as specific substrates and exploring new areas, such as the nature of the receptors that recognize the Man-6-P residues (e.g., the two Man-6-P receptors) and how they transport the acid hydrolases from the Golgi to lysosomes and return to repeat the process. This work has shown how an oligosaccharide recognition molecule serves a critical role in a fundamental cell biological process, the sorting of proteins.

While we have been exploring the role of the Man-6-P recognition system in cell biology, other labs have discovered many more examples of biological functions of protein and lipid-linked oligosaccharides. And many of these functions have proved to be relevant to clinical medicine. As a physician-scientist who strongly believes in the value of basic research in the advancement of clinical medicine, this has been a very rewarding development. Looking back, I\'m very glad that I decided to take the road less traveled.

I thank the many talented students and postdoctorate fellows who have spent time in my lab and participated in the journey into the field of glycobiology and lysosome biogenesis. I am also grateful for the wonderful support of this research provided from the very beginning by the National Institutes of Health.
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